Bank of New York Mellon Corp Has $1.15 Million Stake in Quanterix Co. (NASDAQ:QTRX)

Bank of New York Mellon Corp boosted its stake in shares of Quanterix Co. (NASDAQ:QTRX) by 1.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 108,186 shares of the company’s stock after buying an additional 1,963 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.28% of Quanterix worth $1,150,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Peapack Gladstone Financial Corp bought a new position in shares of Quanterix during the third quarter worth about $131,000. Tallon Kerry Patrick acquired a new stake in Quanterix during the 4th quarter valued at approximately $169,000. Intech Investment Management LLC bought a new position in Quanterix during the 3rd quarter worth approximately $170,000. Janney Capital Management LLC lifted its position in shares of Quanterix by 40.9% in the 4th quarter. Janney Capital Management LLC now owns 33,192 shares of the company’s stock worth $353,000 after purchasing an additional 9,639 shares during the period. Finally, FMR LLC boosted its stake in shares of Quanterix by 112.6% in the 3rd quarter. FMR LLC now owns 30,242 shares of the company’s stock valued at $392,000 after purchasing an additional 16,020 shares during the last quarter. Institutional investors own 86.48% of the company’s stock.

Quanterix Price Performance

NASDAQ QTRX opened at $7.19 on Tuesday. The stock has a market capitalization of $278.80 million, a P/E ratio of -6.78 and a beta of 1.33. The business has a 50 day simple moving average of $8.15 and a 200 day simple moving average of $10.78. Quanterix Co. has a one year low of $6.30 and a one year high of $24.05.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Monday, March 17th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). The business had revenue of $35.16 million for the quarter, compared to the consensus estimate of $34.93 million. Quanterix had a negative return on equity of 11.74% and a negative net margin of 30.12%. Equities analysts expect that Quanterix Co. will post -0.98 earnings per share for the current year.

Analyst Ratings Changes

Separately, Canaccord Genuity Group lowered their target price on shares of Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.